-- U.S. Patent and Trademark Office Reissues Composition of Matter
and Methods of Use Patents for Company's Core CoVal(TM) Fusions --
SAN DIEGO, CA, March 29 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX: NVN) announced today that the U.S. Patent and Trademark Office has
issued Reexamination Certificates for patents U.S. 6,335,183 and U.S.
6,338,952, concluding the ex-parte reexaminations process, and allowing both
patents to be maintained in amended form. These patents form the basis of
Nventa's proprietary CoVal(TM) technology platform, from which the Company's
product candidate pipeline has been generated, and allow patent exclusivity
through 2019. Additional patents owned by Nventa relating to HspE7, the
Company's lead investigational therapeutic vaccine for human papillomavirus
(HPV)-related diseases, allow patent exclusivity through 2021.
The patents, as amended, continue to provide broad coverage for fusion
protein compositions and their use as immunotherapeutic agents to induce or
enhance an individual's immune response. In particular, the patents relate to
protein compositions comprised of mycobacterial heat shock proteins (also
known as stress proteins) covalently fused to viral or cancer antigens, the
DNA encoding for such fusion proteins, as well as methods of inducing or
enhancing an antigen-specific immune response in an individual.
"We are very pleased with the results of the reexamination of the patents
covering our core technology, which is licensed from the Massachusetts
Institute of Technology (M.I.T.) and the Whitehead Institute," said Gregory M.
McKee, President and Chief Executive Officer of Nventa. "This ruling by the
U.S. Patent and Trademark Office validates that our CoVal(TM) fusion proteins
are unique and demonstrate the use of the body's own immune system to mount an
attack against viral or cancerous infections. We are currently poised to
re-enter the clinic with HspE7, our lead CoVal(TM) fusion protein candidate.
We expect to begin a Phase 1 study in mid-2007 in cervical dysplasia patients
using our new formulation of HspE7."
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa, please visit
the website located at www.nventacorp.com.
This press release contains statements which, to the extent that they are
not recitations of historical fact may constitute forward-looking information
under applicable Canadian securities legislation or forward-looking statements
within the meaning of the United States Private Securities Litigation Reform
Act of 1995. Such forward-looking statements or information may include
financial and other projections as well as statements regarding the Company's
future plans, objectives, performance, revenues, growth, profits, operating
expenses or the Company's underlying assumptions. The words "may", "would",
"could", "will", "likely", "expect", "anticipate", "intend", "estimate",
"plan", "forecast", "project" and "believe" or other similar words and phrases
are intended to identify forward-looking statements or information. Persons
reading this press release are cautioned that such statements or information
are only predictions, and that the Company's actual future results or
performance may be materially different.
Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning the coverage
provided by these patents, our ability to re-enter the clinic with our lead
product candidate HspE7 and our expectation to begin a Phase 1 study in
mid-2007 in cervical dysplasia patients using HspE7 plus an adjuvant. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements or
information. Such factors include potential challenges to our patents, risks
associated with obtaining approvals by government agencies and our dependence
on suppliers, collaborative partners and other third parties. Given these
risks and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their
entirety by this cautionary statement.
Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that challenges to our patent, if any, will not be successful, that we
will obtain the necessary regulatory approvals in a timely manner, that we
will obtain timely approval from institutional review boards, that enough
HspE7 will be available to conduct our Phase I study; that we will be able to
procure the necessary amount of adjuvant to conduct our Phase I study, that
the results from additional preclinical work, if any, will be consistent with
the results we have already obtained.
For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings, including
our 2006 Annual Information Form, with Canadian securities regulatory
authorities on SEDAR at http://www.sedar.com.
All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
For further information:
For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA 92121, Dir: (858) 202-4945,